Phase I trial of docetaxel plus lutetium-177-labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer
Jaspreet S. Batra, Muhammad Junaid Niaz, Young E. Whang, Arif Sheikh, Charlene Thomas, Paul J. Christos, Shankar Vallabhajosula, Yuliya Jhanwar, Ana M. Molina, David M. Nanus, Joseph R. Osborne, Neil H. Bander, Scott T. Tagawa
Topics & Concepts
MedicineDocetaxelNeutropeniaProstate cancerToxicityUrologyRadioimmunotherapyProgressive diseaseInternal medicineCabazitaxelFebrile neutropeniaOncologyChemotherapyNuclear medicineCancerMonoclonal antibodyImmunologyAntibodyAndrogen deprivation therapyProstate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsPeptidase Inhibition and Analysis